Patent ID: 8765383

Claim:
A method for determining cancer risk for a human patient, comprising: analyzing a sequence of BRAF in a tissue sample obtained from a premalignant lesion from the lower gastrointestinal (GI) tract of the patient to detect a V600E mutation; measuring a level of an RNA transcript of DUSP6, or its expression product, in the tissue sample; normalizing the level of the RNA transcript of DUSP6, or its expression product, against an expression level of at least one reference gene, to obtain a normalized expression level of DUSP6, comparing the normalized expression level of DUSP6 from the patient to the normalized expression level of DUSP6 in a population with no cancer; and determining that the patient has an increased cancer risk if the normalized expression level of DUSP6 from the patient is increased, or that the patient has a decreased cancer risk if the normalized expression level of DUSP6 from the patient is decreased.